CN101711802A - A coprostasis curative and production method thereof - Google Patents
A coprostasis curative and production method thereof Download PDFInfo
- Publication number
- CN101711802A CN101711802A CN200910171995A CN200910171995A CN101711802A CN 101711802 A CN101711802 A CN 101711802A CN 200910171995 A CN200910171995 A CN 200910171995A CN 200910171995 A CN200910171995 A CN 200910171995A CN 101711802 A CN101711802 A CN 101711802A
- Authority
- CN
- China
- Prior art keywords
- coprostasis
- curative
- present
- product
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a coprostasis curative, which takes seed vessel of blonde psyllium as effective ingredient, and can discharge waste (stubborn stool) in the intestine smoothly. The coprostasis curative provided in the invention characterized in that it contains ingredient (a) and (b) as following: (a) seed vessel of the blonde psyllium; (b) the following formula (1) represents polyoxyethylene polyoxypropylene glycol. In the formula (1), a+c is between 3 and 200, b is between 5 and 67. HO-(C2H4O)a-(C3H6O)b-(C2H4O)c-H (1).
Description
Technical field
The present invention relates to coprostasis curative and manufacture method thereof, more particularly, relate to coprostasis curative and manufacture method thereof that the refuse (stool) that is used for being trapped in enteral is discharged swimmingly.
Background technology
Toxin expelling (detox) typically refers to drains in the body deleterious mineral and toxin to purify intravital process.This toxin expelling is by eliminating constipation, picked-up enriching substance, going on a hunger strike, massage, have a bath to wait and carry out.
Use various coprostasis curatives in the elimination constipation of one of above-mentioned toxin expelling, particularly in recent years,, begin to utilize the composition that comes from plant along with attention to health.As this composition that comes from plant, can enumerate the kind skin of Plantago ovata (Plantago ovata).
This Plantago ovata is the plant of Plantaginaceae (Plantaginaceae) Plantago (Plantago), mainly cultivate in the Mediterranean Region in Europe and India, the U.S., be to form the spike of white, the herbaceous plant for many years of the seed that bears pitchy autumn by spring to the autumn, phlegmatic temperament is rich on the surface of seed (kind skin), has the character (non-patent literature 1) of swelling when touching aqueous vapor.Think that thus the kind skin of Plantago ovata is the preferred substance that is used for the treatment of constipation.
But, stimulate intestinal wall to induce defecation in nature at seed coat of Plantago ovata by swelling, think to be for defecation necessity swimmingly, preparation absorbs moisture equably, with the higher swelling of performance, rather than only arrive in the intestinal tube, this is different with other stimulation component.So, as the research of carrying out in order to improve water dispersible, known technology (patent documentation 1) of for example adding saccharide in order to improve water dispersible and quick-acting, contain water soluble polymer and silicate compound technology (patent documentation 2), be scattered in method (patent documentation 3) in the oils and fats, cooperate the technology (patent documentation 4) of magnesium oxide etc. etc., but these are all insufficient, the refuse that will be trapped in enteral (stool) discharge swimmingly aspect expect that also further improvement is arranged.
Patent documentation 1: the special fair 4-30925 communique of Japan
Patent documentation 2: TOHKEMY 2001-220352 communique
Patent documentation 3: the special fair 6-72106 communique of Japan
Patent documentation 4: TOHKEMY 2001-199894 communique
Non-patent literature 1:Alternative Medline Review, 7 (2), 155-159 (2002).
Summary of the invention
Therefore, problem of the present invention is to provide a kind of coprostasis curative, and it, can be discharged the refuse (stool) that is trapped in enteral as effective ingredient swimmingly with the kind skin of Plantago ovata.
The inventor has carried out deep research in order to solve above-mentioned problem, found that, by the kind skin of combination Plantago ovata and specific surfactant, can absorb moisture quickly and evenly, brings into play higher swelling.And the inventor also finds, mixes by kind skin and above-mentioned surfactant with Plantago ovata, makes coprostasis curative, can improve the mouldability and the manufacturing speed of preparation, thereby finish the present invention.
That is, the present invention relates to a kind of coprostasis curative, it is characterized in that, this coprostasis curative contains following composition (a) and (b):
(a) the kind skin of Plantago ovata,
(b) the polyoxyethylene polyoxypropylene glycol of following formula (1) expression.
HO-(C
2H
4O)
a-(C
3H
6O)
b-(C
2H
4O)
c-H??(1)
(in the formula, a+c is 3～200, and b is 5～67.)
And, the present invention relates to a kind of manufacture method of coprostasis curative, it is characterized in that, the polyoxyethylene polyoxypropylene glycol of kind skin and following formula (1) expression of Plantago ovata is mixed.
HO-(C
2H
4O)
a-(C
3H
6O)
b-(C
2H
4O)
c-H????(1)
(in the formula, a+c is 3～200, and b is 5～67.)
The taking excellence of coprostasis curative of the present invention because the swelling speed of this curative is fast, swelling multiple height, therefore can be discharged the refuse (stool) that is trapped in enteral swimmingly.And coprostasis curative of the present invention is also excellent to the adsorptivity of scatol, the stink in the time of therefore can alleviating defecation when minimizing is trapped in the harmful substance of enteral.
Therefore, coprostasis curative of the present invention can be used for the treatment and the toxin expelling of constipation aptly.
And the manufacture method of coprostasis curative of the present invention can be improved the mouldability and the manufacturing speed of preparation, therefore can make coprostasis curative efficiently.
Description of drawings
Fig. 1 is the electron micrograph in the cross section of the present invention's product 1 of making of embodiment 1.
Fig. 2 is the electron micrograph in the cross section of the relatively product 1 made of embodiment 1.
Fig. 3 is the electron micrograph in the cross section of the relatively product 2 made of embodiment 1.
Fig. 4 is the electron micrograph in the cross section of the relatively product 3 made of embodiment 1.
Fig. 5 be show the present invention's product 1 that embodiment 1 is made and relatively product 1～3 carry out the result's of swelling multiple mensuration accompanying drawing.
Fig. 6 shows that the present invention's product 1 that embodiment 1 is made and commercially available coprostasis curative 1 and 2 carry out the result's that the swelling multiple measures accompanying drawing.
Fig. 7 is the result's of the absorption test that shows that the present invention's product 1 that embodiment 1 is made and commercially available coprostasis curative 1 and 2 carry out scatol a accompanying drawing.
The specific embodiment
The composition of coprostasis curative of the present invention (a) is the kind skin of Plantago ovata.The kind leatherware of this Plantago ovata has can absorb moisture, make the effect of discharging swimmingly after just appropriate softness, the increase (volume).Under the situation of administration once-a-day, the kind skin of this Plantago ovata with each dosage of being grown up be 0.375～5.5g, the amount that is preferably 2.0～5.0g is engaged in the coprostasis curative of the present invention.
And the composition of coprostasis curative of the present invention (b) is the polyoxyethylene polyoxypropylene glycol of following formula (1) expression.
HO-(C
2H
4O)
a-(C
3H
6O)
b-(C
2H
4O)
c-H??(1)
A+c in the formula is 3～200, is preferably 105～160, and b is 5～67, is preferably 5～30.As above-mentioned polyoxyethylene polyoxypropylene glycol, can enumerate PLONON (registered trade mark) series of for example Japan Oil Co's sale and the PEP series that Sanyo Chemical Industries, Ltd. sells, wherein preferred polyoxyethylene (160) polyoxypropylene (30) two pure and mild polyoxyethylene (105) polyoxypropylene (5) glycol, preferred especially polyoxyethylene (160) polyoxypropylene (30) glycol.Under the situation of administration once-a-day, above-mentioned polyoxyethylene polyoxypropylene glycol with each dosage of being grown up be 1～333mg, the amount that is preferably 10～50mg is engaged in the coprostasis curative of the present invention.
With respect to the kind skin of the Plantago ovata of composition (a), by quality ratio, preferably contain the polyoxyethylene polyoxypropylene glycol of 0.002～0.025 mentioned component (b).By in coprostasis curative of the present invention, containing these compositions according to the above ratio, the refuse (stool) that is trapped in enteral can be discharged swimmingly.
And, except mentioned component, further containing at least a crude drug or its extract that are selected from by in the group of following composition (c)～(e) form in the coprostasis curative of the present invention, preferred component (c)～(e) is all contained.
(c) Aloe
(d) Herba Houttuyniae
(e) Senna fruit
Need to prove that in this description, the extract of crude drug is meant extract, its dry thing of the liquid state that the conventional method according to records such as Pharmacopeias of Japan extracts, i.e. (drying) extract, tincture etc. from above-mentioned crude drug.
Among the above-mentioned crude drug, the Aloe of composition (c) is that the juice drying that the leaf by the hybrid that opens general Aloe (Cape Aloe) (also claiming Aloe ferox Miller (Aloe ferox Miller)) or itself and African Aloe (Aloe africana Miller) or queen brocade Aloe (Aloe spicata Baker) of Aloeaceae (Aloaceae) Aloe (Aloe) obtains forms.By this Aloe is coupled in the coprostasis curative of the present invention, can promote enterokinesia, give the effect of just discharging swimmingly that makes.And under the situation of administration once-a-day, crude drug in whole (extract) is counted 150～380mg to this Aloe by being converted into, the amount that is preferably 185～375mg is engaged in the coprostasis curative of the present invention with each dosage of being grown up.
And the Herba Houttuyniae of composition (d) is the aerial parts at florescence that Saururaceae (Saururaceae) Herba Houttuyniae belongs to the Herba Houttuyniae (Houttuynia cordata) of (HouttuyniaThunberg).By this Herba Houttuyniae is coupled in the coprostasis curative of the present invention, can assist the discharge of refuse, give the effect that improves pachylosis.In addition, under the situation of administration once-a-day, this Herba Houttuyniae with each dosage of being grown up be 50～2500mg, the amount that is preferably 200～600mg is engaged in the coprostasis curative of the present invention.
In addition, the Senna fruit of composition (e) is that Caesalpiniaceae (Caesalpiniaceae) Senna fruit belongs to the narrow leaf Senna fruit (Cassia angustifolia Vahl) of (Senna) or the lobule of cassia acutifolia Delile (pulse family) (Cassia angustifoliaDelile (Leguminosae)).By this Senna fruit is coupled in the coprostasis curative of the present invention, can promote enterokinesia, make just and discharge swimmingly.In addition, under the situation of administration once-a-day, this Senna fruit be grown up each dosage by Sennoside A and sennoside B total amount count 1～24mg, the amount that is preferably 6～16mg is engaged in the coprostasis curative of the present invention.
In addition, except mentioned component (a)～(e), can also contain crude drug or its extracts more than a kind or 2 kinds such as Rhizoma Smilacis Glabrae, Rhizoma Curcumae in the coprostasis curative of the present invention.Among these crude drugs, Rhizoma Smilacis Glabrae is the tuber of Smilacaceae (Smilacaceae) smilax (Smilax) Rhizoma Smilacis Glabrae (Smilax glabra), known its to little pus cook, pachylosis etc. is effective.And Rhizoma Curcumae is the tuber of Zingiberaceae (Zingiberaceae) Curcuma (Curcuma) Rhizoma Curcumae (Curcuma zedoaria), known its to inappetence, dyspepsia, stomach a little less than, hyperalimentation, heartburn etc. be effective.By these crude drugs or its extract are coupled in the coprostasis curative of the present invention, can make coprostasis curative of the present invention become excellent more.And, under the situation of administration once-a-day, these crude drugs or its extract with each dosage of being grown up be 30～3000mg, the amount that is preferably 100～750mg is engaged in the coprostasis curative of the present invention.
Except the mentioned component that will comprise each dosage of being grown up, the coprostasis curative of the present invention that contains mentioned component can be made according to conventional method.And, can in manufacture process, mix known formulation additives etc. as required.
As known formulation additives, can enumerate sweeting agents such as aspartame, glycyrrhizic acid dipotassium, sucralose, Radix Glycyrrhizae powder; Excipient such as hydroxypropyl cellulose, D-Sorbitol, D-mannitol, sodium citrate hydrate, crystalline cellulose, reduction maltose, white sugar, lactose; Flowing agents such as Talcum, light anhydrous silicic acid, aqueous silicon dioxide; Spice such as L-menthol; Food coloring such as caramel, tar colorant.
And, to the not restriction especially of dosage form of coprostasis curative of the present invention,, can enumerate for example capsule, granula subtilis, tablet, fast disintegrant, powder, granule etc. so long as the per os preparation gets final product, especially preferably make granule.Particularly the dosage form of therapeutic agent for constipation of the present invention is being made under the situation of granule, preferably carried out extruding pelletization after mixing mentioned component (a) and composition (b), so the granule of making can absorb moisture quickly and evenly, has given play to higher swelling.
The coprostasis curative of the present invention that so obtains by 1～2 time on the 1st, take on an empty stomach, can improve constipation.
As the particularly preferred example of coprostasis curative of the present invention, can enumerate the example that contains following composition in 1 feed ration.This coprostasis curative can divide 1 feed ration to be taken for several times.
(a) the kind skin 2～5g of Plantago ovata
(b) polyoxyethylene (160) polyoxypropylene (30) glycol 10～50mg
(c) Aloe extract 185～375mg
(being scaled crude drug in whole is 370～750mg)
(d) Herba Houttuyniae powder 200～600mg
(e) calcium sennoside (Calcium Sennosides) 16.5～44mg
(count 6～16mg) with Sennoside A and sennoside B total amount
Coprostasis curative of the present invention is above-mentioned prescription, and principal agent (kind skin, Aloe and the Senna fruit of Plantago ovata) exceeds about 18～50% the defecation effect that worth expectation is more powerful with the more existing commercially available emplastic of proportioning of adjuvant drug (Herba Houttuyniae).
Embodiment
Be described more specifically the present invention by the following examples, but the present invention is not subjected to any restriction of this embodiment.
The manufacturing of coprostasis curative (1):
Prescription (part on the 1st) according to following table 1 utilizes following manufacture method to make each coprostasis curative.And, the cross section of each coprostasis curative of producing is observed with ultramicroscope.The electron micrograph in the cross section of each coprostasis curative is seen Fig. 1～4.
[table 1]
| The present invention's |
Relatively |
Relatively |
Relatively |
|
| The kind skin of Plantago ovata | ??4400 | ??4400 | ??4400 | ??4400 |
| Polyoxyethylene (160) polyoxypropylene (30) glycol 1) | ??20 | ??- | ??- | ??- |
| Sucrose stearate 2) | ??- | ??- | ??20 | ??- |
| Polyoxyethylene (20) sorbitol anhydride oleate 3) | ??- | ??- | ??- | ??20 |
| Aloe extract 4) | ??375 | ??375 | ??375 | ??375 |
| The present invention's |
Relatively |
Relatively |
Relatively |
|
| Herba Houttuyniae powder | ??500 | ??500 | ??500 | ??500 |
| Calcium sennoside 5) | ??40 | ??40 | ??40 | ??40 |
| Sweeting agent | ??112 | ??112 | ??112 | ??112 |
| Excipient | ??500 | ??500 | ??500 | ??500 |
| Flowing agent | ??24 | ??24 | ??24 | ??24 |
| Spice | In right amount | In right amount | In right amount | In right amount |
Numerical value unit in the table is mg.
1) PLONON#188P (Japan Oil Co's manufacturing)
2) SURFHOPE SE PHARMA J-1816 (Mitsubishi-kagaku Foods Corp.'s manufacturing)
3) polysorbate80 (Sanyo Chemical Industries, Ltd.'s manufacturing)
4) being scaled crude drug in whole is 750mg
5) count 14.4mg with the total amount of Sennoside A and sennoside B
＜manufacture method 〉
With seed coat of Plantago ovata, Aloe extract, calcium sennoside, Herba Houttuyniae powder, part sweeting agent, part excipient uniform mixing, drop into dark river high-speed mixer FS-GS200E (dark river Powtec makes), polyoxyethylene (160) polyoxypropylene (30) glycol, remaining excipient are dissolved in the mixed solvent of ethanol, pure water, add this solution, mixing 3 minutes.
Then; with vertical comminutor this mixing thing is carried out extruding pelletization; carry out drying with Fuji Paudal ventilation drying machine (Fuji Paudal manufacturing); with moral longevity formula vibrosieve (the work manufacturing of moral longevity) granulate; add flowing agent, remaining sweeting agent, spice etc.; fully mix, obtain purpose pelletize thing.Wherein, relatively in the product, except not adding polyoxyethylene (160) polyoxypropylene (30) glycol or, similarly making with the present invention's product 1 with sucrose stearate, the replacement of polyoxyethylene (20) sorbitol anhydride oleate.
The present invention's product 1 are made by the kind skin of Plantago ovata and polyoxyethylene (160) polyoxypropylene (30) glycol are mixed, compare with product 3 relatively with the relatively product 1 that do not add surfactant and the relatively product 2 that cooperated the different surfaces activating agent, formability, manufacturing speed are improved.
And, carry out electron microscope observation by cross section, can find, with the relatively product 1 that do not add surfactant, be combined with the relatively product 2 of different surfaces activating agent and compare with product 3 relatively to each coprostasis curative, the cavity of the granule sectional area of the present invention's product 1 is big, is fluffy softish granule.
Test example 1
The sense test:
With 3 experimenter persons (panelist) taking to feel and carry out freely estimating to each coprostasis curative of making among the embodiment 1 (the present invention's product 1 and relatively product 1～3).
＜take the evaluation methodology of sense 〉
4 kinds of coprostasis curatives that embodiment 1 is made respectively 1 wrap (1/4 feed ration) uses 100mL respectively in different cups aqueous suspension, and nose is estimated near the cup smelling the odour after 1 minute.And, allow experimenter person drink each 1 bag of 4 kinds of coprostasis curatives of manufacturing among the embodiment 1, the easiness of drinking is estimated.
The present invention's product 1 free from extraneous odour is compared with product 3 relatively with the relatively product 2 that are combined with the different surfaces activating agent, and it is attached to aspect such as tooth and improves in the oral cavity, and it is comfortable to take sense.On the other hand, though product 2 frees from extraneous odour relatively are attached to tooth in the oral cavity, it is poor to take sense, and relatively product 3 have special plastics to distinguish the flavor of, and are attached to tooth in the oral cavity, and it is poor especially to take sense.
Test example 2
Swelling test (1):
Each coprostasis curative of embodiment 1 being made with following method (the present invention's product 1 and relatively product 1～3) carries out swelling to be tested.It the results are shown in Figure 5.
＜swelling test method 〉
Each coprostasis curative is put into sieve respectively No. 30, cover lid, level was shaken 3 minutes, beat vibration simultaneously gently.Then, sieve is gone up residual 0.5g sample put into the 20mL graduated cylinder, after beaing gently, read volume (V1).In graduated cylinder along wall to wherein adding 15mL water, beat the degassing gently.Then, reading volume (V2) after 1 minute, after 5 minutes, after 10 minutes, after 20 minutes and after 30 minutes once more.According to these values that reads, utilize following formula to obtain the swelling multiple.
Swelling multiple=V2/V1
As shown in Figure 5, the swelling multiple of the present invention's product 1 after 30 minutes is 4.2 times, but relatively product 1 are 3.6 times, and relatively product 2 are 3.5 times, and relatively product 3 are 3.5 times.And the swelling multiple of all coprostasis curatives did not change along with the process of time after 30 minutes.In addition, relatively product 1～3 reach above-mentioned swelling multiple and have expended 30 minutes, and relative therewith, and the present invention's product 1 reach and are equal to relatively the swelling multiple of product 1～3 and used about 5 minutes.
Therefore, compare with the diverse relatively product 2～3 of relatively product 1 that do not add surfactant and surfactant, the swelling speed of the present invention's product 1 is fast, swelling multiple height.
Test example 3
Swelling test (2):
The mensuration of swelling multiple is similarly carried out with test example 2 in the present invention's product 1 and commercially available coprostasis curative 1 and 2 of using embodiment 1 to make.The measurement result of swelling multiple is seen Fig. 6.Wherein, commercially available coprostasis curative 1 and 2 contains kind skin 2000～5000mg and the Sennoside A and the sennoside B 30～50mg of Plantago ovata in 1 feed ration.Need to prove, do not contain Aloe extract, Herba Houttuyniae powder and surfactant in two kinds of commercially available coprostasis curatives.
As shown in Figure 6, rise from the outset about 30 seconds all coprostasis curatives all swelling a lot, but the swelling speed of the present invention's product 1 is higher than commercially available coprostasis curative 1 and 2.And the swelling multiple of all coprostasis curatives did not change along with the process of time after 30 minutes.Swelling multiple after 30 minutes is compared, found that, the present invention's product 1 have been compared swelling about 1.2 times with commercially available coprostasis curative 1, have compared swelling about 1.7 times with commercially available coprostasis curative 2.
Test example 4
The adsorption test of scatol:
The present invention's product 1 and commercially available coprostasis curative 1 and 2 of using embodiment 1 to make utilize following method to carry out the adsorption test of the scatol of one of stink.It the results are shown in Figure 7.
＜scatol adsorption test 〉
In being applied with the glass centrifugal precipition tube of silicon coating, puts into 50mL each coprostasis curative (each is all unified for containing the amount that is equivalent to the 600mg Plantago ovata) respectively, with dissolve with methanol 100mg scatol, after making 20mL, with 50mL is in the scatol adding glass centrifugal precipition tube of 15 μ g/mL, in 37 ℃ of rotations 1 hour with Mcllvaine buffer (pH7.4) dilution.Then, with 2,000rpm centrifugalize 20 minutes is measured the 5mL supernatant and is added threaded test tube (screw-cap tube) to the glass centrifugal precipition tube, again with 3, and centrifugal 30 minutes of 000rpm.The supernatant that herein obtains filters with 0.45 μ m filter, and filtrate is diluted 10 times with Mcllvaine buffer (pH7.4).In 100 μ L, add 3 μ g/mL 2 methyl indoles, 100 μ L as internal standard substance matter, with HPLC scatol is carried out quantitatively.
As shown in Figure 7, the scatol adsorption rate of the present invention's product 1 is 20.4 ± 1.8%, and the scatol adsorption rate of commercially available coprostasis curative 1 is 17.8 ± 0.8%, and the scatol adsorption rate of commercially available coprostasis curative 2 is 12.9 ± 1.1%.In the calibrating of Tukey type multiple comparisons, the present invention's product 1 are compared with other commercially available coprostasis curatives and are demonstrated the adsorption rate with notable difference.
Test example 5
Take test:
Allow 10 to be subjected to the experimenter person of constipation puzzlement to take 2 times on the 1st, 1,1 time 1～2 bag of the present invention's product of embodiment 1 manufacturing in 4 days, take with one glass of cold water or warm water.After taking, allow these experimenter persons that the quick-acting of improving effect, effect, Yi Yinxing, taste, the whole balance aspect of symptom are estimated.Its result is as follows.
＜symptom improve effect assessment
(evaluation) (number)
Satisfied 2 people
Slightly satisfied 6 people
Medium 1 people
Slightly dissatisfied 1 people
Dissatisfied 0 people
The quick-acting of＜effect 〉
(evaluation) (number)
Satisfied 0 people
Slightly satisfied 8 people
Medium 0 people
Slightly dissatisfied 0 people
Dissatisfied 2 people
＜Yi Yinxing 〉
(evaluation) (number)
Easily drink 6 people
Common 3 people
Difficulty is drunk 1 people
＜taste 〉
(evaluation) (number)
3 people
Common 6 people
Wish change of pace 1 people
＜whole balance 〉
(evaluation) (number)
Satisfied 2 people
Slightly satisfied 7 people
Medium 0 people
Slightly dissatisfied 1 people
Dissatisfied 0 people
By above result as can be known, coprostasis curative of the present invention is being excellent aspect the quick-acting of improving effect, effect of symptom, Yi Yinxing, taste, the whole balance.
The manufacturing of coprostasis curative (2):
According to following prescription (part on the 1st), make coprostasis curative (the present invention's product 2) similarly to Example 1.
(prescription)
Component content (mg)
The kind skin 4000 of Plantago ovata
Polyoxyethylene (160) polyoxypropylene (30) glycol
1)20
Aloe extract
2)375
Herba Houttuyniae powder 500
Calcium sennoside
3)40
Sweeting agent 100
Excipient 500
Flowing agent 24
Spice is an amount of
1) PLONON#188P (Japan Oil Co's manufacturing)
2) being scaled crude drug in whole is 750mg
3) count 14.4mg with Sennoside A and sennoside B total amount
Identical with the present invention's product 1, the present invention's product 2 are excellence aspect the quick-acting of improving effect, effect of symptom, Yi Yinxing, taste, whole balance.And, similarly the present invention's product 2 are carried out swelling test with test example 2, obtain and add the swelling multiple of water after 1 minute, be 2.4 times.
The manufacturing of coprostasis curative (3):
According to following prescription (part on the 1st), make coprostasis curative (the present invention's product 3) similarly to Example 1.
(prescription)
Component content (mg)
The kind skin 3000 of Plantago ovata
Polyoxyethylene (160) polyoxypropylene (30) glycol
1)15
Aloe extract
2)300
Herba Houttuyniae powder 500
Calcium sennoside
3)40
Rhizoma Smilacis Glabrae powder 150
Excipient 220
Flowing agent 24
Spice is an amount of
1) PLONON#188P (Japan Oil Co's manufacturing)
2) being scaled crude drug in whole is 600mg
3) count 14.4mg with the total amount of Sennoside A and sennoside B
Identical with the present invention's product 1, the present invention's product 3 are excellence aspect the quick-acting of improving effect, effect of symptom, Yi Yinxing, taste, whole balance.And, similarly the present invention's product 3 are carried out swelling test with test example 2, obtain and add the swelling multiple of water after 1 minute, be 2.2 times.
The manufacturing of coprostasis curative (4):
According to following prescription (part on the 1st), make coprostasis curative (the present invention's product 4) similarly to Example 1.
(prescription)
Component content (mg)
The kind skin 3000 of Plantago ovata
Polyoxyethylene (160) polyoxypropylene (30) glycol
1)15
Aloe extract
2)300
Herba Houttuyniae powder 500
Calcium sennoside
3)40
Excipient 270
Flowing agent 24
Spice is an amount of
1) PLONON#188P (Japan Oil Co's manufacturing)
2) being scaled crude drug in whole is 600mg
3) count 14.4mg with the total amount of Sennoside A and sennoside B
Identical with the present invention's product 1, the present invention's product 4 are excellence aspect the quick-acting of improving effect, effect of symptom, Yi Yinxing, taste, whole balance.And, similarly the present invention's product 4 are carried out swelling test with test example 2, obtain and add the swelling multiple of water after 1 minute, be 2.4 times.
The manufacturing of coprostasis curative (5):
According to following prescription (part on the 1st), make coprostasis curative (the present invention's product 5) similarly to Example 1.
(prescription)
Component content (mg)
The kind skin 4000 of Plantago ovata
Polyoxyethylene (105) polyoxypropylene (5) glycol
1)20
Aloe extract
2)375
Herba Houttuyniae powder 500
Calcium sennoside
3)40
Sweeting agent 112
Excipient 500
Flowing agent 24
Spice is an amount of
1) PEP-101 (Sanyo changes into industry)
2) being scaled crude drug in whole is 750mg
3) count 14.4mg with the total amount of Sennoside A and sennoside B
Identical with the present invention's product 1, the present invention's product 5 are excellence aspect the quick-acting of improving effect, effect of symptom, Yi Yinxing, taste, whole balance.
Embodiment 6
The manufacturing of coprostasis curative (6):
According to following prescription (part on the 1st), make coprostasis curative (the present invention's product 6) similarly to Example 1.
(prescription)
Component content (mg)
The kind skin 3000 of Plantago ovata
Polyoxyethylene (105) polyoxypropylene (5) glycol
1)15
Aloe extract
2)300
Herba Houttuyniae powder 500
Calcium sennoside
3)40
Excipient 270
Flowing agent 24
Spice is an amount of
1) PEP-101 (Sanyo changes into industry)
2) being scaled crude drug in whole is 600mg
3) count 14.4mg with the total amount of Sennoside A and sennoside B
Identical with the present invention's product 1, the present invention's product 6 are excellence aspect the quick-acting of improving effect, effect of symptom, Yi Yinxing, taste, whole balance.
The industry practicality
Coprostasis curative of the present invention can be discharged the refuse (stool) that is trapped in the intestines smooth and easyly, therefore can be used for treatment and the toxin expelling of constipation.
Claims (6)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-254531 | 2008-09-30 | ||
| JP2008254531 | 2008-09-30 | ||
| JP2009-181512 | 2009-08-04 | ||
| JP2009181512A JP5415867B2 (en) | 2008-09-30 | 2009-08-04 | Anti-constipation drug and method for producing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101711802A true CN101711802A (en) | 2010-05-26 |
| CN101711802B CN101711802B (en) | 2012-11-07 |
Family
ID=42295815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101719957A Expired - Fee Related CN101711802B (en) | 2008-09-30 | 2009-09-24 | A coprostasis curative and production method thereof |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP5415867B2 (en) |
| CN (1) | CN101711802B (en) |
| TW (1) | TWI439280B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104642869A (en) * | 2015-01-28 | 2015-05-27 | 四川健之源科技有限公司 | Health food with function of improving constipation |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5631721B2 (en) * | 2010-12-17 | 2014-11-26 | ビオフェルミン製薬株式会社 | Gastrointestinal hypersensitizer |
| JP5842521B2 (en) * | 2011-09-30 | 2016-01-13 | ゼリア新薬工業株式会社 | Constipation medication |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011169D0 (en) * | 2000-05-10 | 2000-06-28 | Reckitt & Colmann Prod Ltd | Improvements in or relating to medicinal compositions |
| JP4756223B2 (en) * | 2006-02-15 | 2011-08-24 | 有限会社めぐみ薬局 | Skin improvement additive and beverage, cosmetic cream, lotion and lotion using the same |
| JP2008120719A (en) * | 2006-11-10 | 2008-05-29 | Sato Pharmaceutical Co Ltd | Purgative |
-
2009
- 2009-08-04 JP JP2009181512A patent/JP5415867B2/en active Active
- 2009-09-23 TW TW98132137A patent/TWI439280B/en not_active IP Right Cessation
- 2009-09-24 CN CN2009101719957A patent/CN101711802B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104642869A (en) * | 2015-01-28 | 2015-05-27 | 四川健之源科技有限公司 | Health food with function of improving constipation |
| CN104642869B (en) * | 2015-01-28 | 2017-09-26 | 四川健之源科技有限公司 | A kind of health food with bowel relaxing functions |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI439280B (en) | 2014-06-01 |
| HK1143076A1 (en) | 2010-12-24 |
| JP2010106008A (en) | 2010-05-13 |
| TW201021817A (en) | 2010-06-16 |
| JP5415867B2 (en) | 2014-02-12 |
| CN101711802B (en) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wasswa et al. | The in-vitro ascaricidal activity of selected indigenous medicinal plants used in ethno veterinary practices in Uganda | |
| CN104840967A (en) | Taste correction method for oral liquid preparation of traditional Chinese medicine containing ethyl alcohol | |
| CN101658295B (en) | Health-care food for clearing and nourishing throat | |
| CN104288609A (en) | Traditional Chinese medicine composition curing stomach fire flaming gingivitis and preparation method for traditional Chinese medicine composition | |
| CN112915187B (en) | Traditional Chinese medicine composition capable of dispelling cold and removing dampness, preparation method and application | |
| CN105079309A (en) | Composition for relaxing bowels to relieve constipation | |
| CN101711802A (en) | A coprostasis curative and production method thereof | |
| KR20170110895A (en) | Antimicrobial compositions for perfume containing natural material extract and the manufacturing method thereof | |
| CN102600358B (en) | Traditional Chinese laxative medicine and product thereof | |
| RU2431494C1 (en) | Antiparasitic tea | |
| CN109432242A (en) | A kind of larch arabinogalactan preparation method and its application in terms of medical treatment | |
| CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
| CN104643078A (en) | Compound dendrobium officinale health oral liquid and preparation method thereof | |
| CN108853201B (en) | Compound Chinese herbal medicine preparation, preparation method and application | |
| CN104922548A (en) | Chinese herbal preparation for treatment of ascariasis | |
| CN105287328A (en) | Manuka honey toothpaste for pregnant women and preparation method of toothpaste | |
| KR19980038705A (en) | Healthy nutritional composition with constipation and odor | |
| Dande et al. | Laxative activity of Raphanus sativus L. leaf | |
| CN109464540A (en) | A kind of alleviation oral cavity and the spray of throat discomfort and preparation method thereof | |
| CN100556397C (en) | Skin care liquid of mongolian snakegourd | |
| RU2743292C1 (en) | Agent for treating cholelithiasis and urolithiasis | |
| TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
| CN102526526A (en) | Chinese medicine for treating periodontitis with deficiency of kidney 'Qi', and preparation method and administration mode of Chinese medicine | |
| CN101455713A (en) | Composition for preparing products capable of loosening the bowel to relieving constipation | |
| CN113520957A (en) | Chinese herbal medicine toothpaste formula for gingivitis and gingival atrophy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1143076 Country of ref document: HK |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1143076 Country of ref document: HK |
|
| C56 | Change in the name or address of the patentee |
Owner name: PANA KAYIYA CO., LTD. PHARMACEUTICAL Free format text: FORMER NAME: KYOEI PHARMACEUTICAL INDUSTRY LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Toyama County Patentee after: Pana Ke Ya Medicine Pharmaceutical Co. Ltd. Patentee after: SS Pharmaceutical Co., Ltd. Address before: Toyama County Patentee before: Ss Pharmaceutical Co Patentee before: SS Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121107 Termination date: 20150924 |
|
| EXPY | Termination of patent right or utility model |